Last updated: 4/27/2020
Latest updates are in the scientific articles section!Click HERE to go to the "Official" Optune™ Website
High compliance with Optune™ linked to greatest survival benefit for glioblastoma 29% 5 year survival in high compliance group compared to 4.5% in control group.(Added 1/26/19)
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.(Added 8/29/2020)
Read this if you are going to use Optune™ - it will help prevent the most comon problems!No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators (Added 11/21/17)
Results from the trial for newly diagnoes GBM: 5 year survival rate more than double the standard of care! (added 9/24/17)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma This may become the new standard of care for Glioblastoma multiforme! (added 12/15/15)
FDA Approves Optune for Newly Diagnosed Glioblastoma Patients. Risk of death reduced by 37%!
Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients Optune can now be used even if you have a non programmable shunt!New data on how Tumor Treating Fields Works
The name of the treatment has been changed from Novocure TTF100-A to Optune™ on 11/14/2014
|
Optune™ is a unique new form of treatment for brain tumors: it uses Tumor Treating Fields (TTF) to kill dividing cells. These fields are delivered by removable transducer arrays that are placed on the head. Click HERE for a news video about the Novocure NovoTTF-100A! Click on the links below for more information on Optune™!
|  |